Novel secreted polypeptide zsig87
OwnerPaul O. Sheppardinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to polynucleotide and polypeptide molecules for zsig87, a novel secreted protein. The polynucleotides encoding zsig87, may, for example, be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
Claims21
An isolated polynucleotide encoding a polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 27 (Arg) to amino acid number 56 (Cys);
- (b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 16 (Glu) to amino acid number 84 (Pro);
- and
- (c) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 84 (Pro).
An expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide comprising an amino acid sequence as shown in SEQ ID NO:2 from amino acid number 16 (Glu) to amino acid number 84 (Pro);
- and
- a transcription terminator.
A DNA construct encoding a fusion protein, the DNA construct comprising:
- a first DNA segment encoding a polypeptide comprising a sequence of amino acid residues selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:
- 2 from residue number 1 (Met) to residue 15 (Glu);
- (b) the amino acid sequence of SEQ ID NO:
- 2 from residue number 27 (Arg) to amino acid number 84 (Pro);
- and
- (b) the amino acid sequence of SEQ ID NO:
- 2 from residue number 16 (Glu) to amino acid number 84 (Pro);
- and
- at least one other DNA segment encoding an additional polypeptide,
- wherein the first and other DNA segments are connected in-frame;
- and
- encode the fusion protein.
An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 27 (Arg) to amino acid number 56 (Cys);
- (b) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 16 (Glu) to amino acid number 84 (Pro);
- and
- (c) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 84 (Pro).
A method for detecting a genetic abnormality in a patient, comprising:
- obtaining a genetic sample from a patient;
- producing a first reaction product by incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence;
- visualizing the first reaction product;
- and
- comparing said first reaction product to a control reaction product from a wild type patient, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.
A method for detecting a cancer in a patient, comprising:
- obtaining a tissue or biological sample from a patient;
- labeling a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1;
- incubating the tissue or biological sample with under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence;
- visualizing the labeled polynucleotide in the tissue or biological sample;
- and
- comparing the level of labeled polynucleotide hybridization in the tissue or biological sample from the patient to a normal control tissue or biological sample,
- wherein an increase or decrease in the labeled polynucleotide hybridization to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of a cancer in the patient.
Dependencies are inferred from the claim text.